Trial · NCT01687478
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS) | Olanzapine + Fluoxetine | -15.92 | Standard Error 1.20 | Units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS) | Placebo + Fluoxetine | -14.30 | Standard Error 1.28 | Units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale | Olanzapine + Fluoxetine | -1.43 | Standard Error 0.15 | Units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale | Placebo + Fluoxetine | -1.63 | Standard Error 0.16 | Units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS) | Olanzapine + Fluoxetine | 0.03 | Standard Deviation 1.71 | units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS) | Placebo + Fluoxetine | -0.14 | Standard Deviation 1.72 | units on a scale | |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Physical Functioning | 2.20 | Standard Deviation 7.51 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Physical Functioning | 0.70 | Standard Deviation 7.47 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Role-Physical | 3.99 | Standard Deviation 11.79 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Role-Physical | 3.93 | Standard Deviation 11.23 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Bodily Pain | 6.81 | Standard Deviation 12.05 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Bodily Pain | 0.02 | Standard Deviation 11.30 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | General Health | 5.82 | Standard Deviation 11.49 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | General Health | 2.84 | Standard Deviation 9.44 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Vitality | 7.43 | Standard Deviation 13.54 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Vitality | 5.04 | Standard Deviation 9.83 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Social Functioning | 6.13 | Standard Deviation 13.55 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Social Functioning | 4.56 | Standard Deviation 11.78 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Olanzapine + Fluoxetine | Role-Emotional | 6.61 | Standard Deviation 12.39 | units on a scale |
| Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36) | Placebo + Fluoxetine | Role-Emotional | 6.71 | Standard Deviation 12.12 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01687478/results